Two new oral antidiabetics: Both poorly assessed

Prescrire International

Volumn 11, Issue 62, 2002, Pages 170-176

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; BIGUANIDE DERIVATIVE; CONTRACEPTIVE AGENT; DIGOXIN; GLIBENCLAMIDE; GLUCOSE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; RANITIDINE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE; VOGLIBOSE; WARFARIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; THIAZOLE DERIVATIVE;

ANEMIA; ARTICLE; BLADDER TUMOR; BLOOD GLUCOSE MONITORING; BODY WEIGHT DISORDER; CARDIOVASCULAR RISK; CLINICAL TRIAL; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DETERMINATION; DRUG EFFICACY; DRUG FATALITY; DRUG METABOLISM; DRUG TOLERABILITY; EDEMA; EUROPEAN UNION; FETOTOXICITY; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HEMODILUTION; HEPATIC ENCEPHALOPATHY; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIVER INJURY; LIVER TOXICITY; META ANALYSIS; METABOLIC DISORDER; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRACTICE GUIDELINE; SODIUM RETENTION; WATER RETENTION; WEIGHT GAIN; COMPARATIVE STUDY; DRUG APPROVAL; DRUG EFFECT; DRUG SCREENING; EUROPE; EVALUATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DRUG APPROVAL; DRUG EVALUATION; EUROPE; EVALUATION STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; SULFONYLUREA COMPOUNDS; THIAZOLES;

EID: 0036883996     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Prescrire Editorial Staff "Managing type 2 diabetes" Prescr Int 2001; 10 (55): 158.
2. Anaes "Stratégie de prise en charge do patient diabétique de type 2 à l'exclusion de la prise en charge des complications" mars 2000: 161 pages.
3. Prescrire Editorial Staff "Management of type 2 diabetes" Prescr Int 1999; 8 (43): 147-152
4. Veterans Health Administration "Clinical practice guideline for the management of diabetes mellitus in the primary care setting" Version 2.2, December 1999: 185 pages. Website: http://www.va.gov/health/diabetes. (module G, pages 32-33).
5. Institute for Clinical Systems Improvement "Management of type 2 diabetes mellitus". Octobre 2001. 62 pages. Website: http://www.icsi.org.
6. Meltzer S et al. "Lignes directrices de pratique clinique 1998 pour le traitement du diabète au Canada" CMAJ 1998; 159 (suppl. 8): 1-31. Updated in: Gerstein HC et al. "CDA position statement regarding the UKPDS and revision of diabetes clinical practice guidelines accounting for the UKPDS results". Website: http://www.diabetes.ca/prof consulted on 17 February 2002.
7. French agency for health product safety "Recommandations pour le traitement médica-menteux du diabète de type 2 (I " Press Med 1999; 28 (28): 1527-1533. Website: http://afssaps.sante.fr.
8. "Troglitazone". in: "Martindale The complete drug reference" 33rd ed, The Pharmaceutical Press, London 2002: 337.
9. The European Agency for the Evaluation of Medicinal Products - Committee for Proprietary Medicinal Products "European Public Assessment Report (EPAR) - Actos" 7 January 2002. Website http://www.eudra.org consulted on 11 January 2002.
10. The European Agency for the Evaluation of Medicinal Products-Committee for Proprietary Medicinal Products "European Public Assessment Report (EPAR) - Avandia" 3 December 2001. Website http://www.eudra.org consulted on 6 December 2001.
11. GlaxoSmithKline "GlaxoSmithKline announces RECORD. A benchmark study to determine effects of reducing insulin resistance on cardiovascular risk" Press release (3 pages), undated, received by Prescrire on 19 March 2002.
12. Brunetti P "Pioglitazone: the future" Int J Clin Pract 2001; (suppl. 121): 36.
13. SmithKline Beecham "Avandia - Dossier de transparence volume 2" 27 April 2000: 110 pages.
14. Raskin P et al. "Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes" Diabetologia 2000; 43: 278-284.
15. Nolan JJ et al. "Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus" Diabet Med 2000; 17: 287-294.
16. Lebovitz HE et al. "Rosiglitazone monotherapy is effective in patients with type 2 diabetes" J Clin Endocrinol Metab 2001; 86 (1): 280-288 + (4): 1659.
17. Phillips LS et al. "Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes" Diabetes Care 2001; 24 (2): 308-315.
18. Wolffenbuttel BHR et al. "Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients" Diabet Med 2000; 17: 40-47.
19. National Institute for Clinical Excellence "The clinical effectiveness and cost effectiveness of rosiglitazone for type 2 diabetes mellitus" August 2000: 107 pages.
20. Xixing Z et al. "Rosiglitazone improves glycemic control in chinese patients with type 2 diabetes mellitus in combination with sulfonylurea" Diabetes Care 2001; 50 (suppl. 2): 135 (abstract 542-P). Website www.diabetes.org consulted on 31 January 2002.
21. Food and Drug Administration "Avandia Statistical review and evaluation NDA 21-071 SE1-001" March 28, 2000. Website http://www.fda.gov consulted on 31 January 2002.
22. Food and Drug Administration "Avandia - Statistical review and evaluation NDA 21-071" May 11, 1999. Website http://www.fda.gov consulted on 31 January 2002.
23. Fonseca V et al. "Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus" JAMA 2000, 283 (13): 1695-1702.
24. Gomez-Perez FJ et al. "Rosiglitazone-metformin combination therapy improves glycemic control in Mexican patients with type 2 diabetes" Diabetes Care 2001; 50 (suppl. 2): 436 (abstract 1818-PO). Website www.diabetes.org consulted on 31 January 2002.
25. Charbonnel B et al. "Rosiglitazone is superior to glyburide in reducing fasting plasma glucose after 1 year of treatment in type 2 diabetic patients" Diabetes 1999; 48 (suppl. 1): 114 (abstract 0494 ).
26. Food and Drug Administration - Center for drug evaluation and research "Actos - Statistical review(s) 021073" 17 June 1999: 73 pages.
27. Aronoff S et al. "Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes" Diabetes Care 2000; 23 (11): 1605-1611.
28. Rosenblatt S et al. "The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus" Coronary Artery Disease 2001; 12 (5): 413-423.
29. The National Institute for Clinical Excellence "The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus" March 2001: 88 pages.
30. Chilcott J et al. "A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus" Clin Ther 2001; 23 (11): 1792-1823.
31. Kipnes MS et al. "Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study" Am J Med 2001; 111: 10-17.
32. Miyazaki Y et al. "Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone" Diabetes Care 2001; 24 (4): 710-719.
33. Einhorn D et al. "Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study" Clin Ther 2000; 22 (12): 1395-1409.
34. Baba S "Pioglitazone: A review of japanese clinical studies" Curr Med Res Opinion 2001; 17 (3): 166-189.
35. "Avandia°". In: "Physicians' Desk Reference", Medical Economies Company, Montvale 2002: 1490-1494.
36. Scherbaum W et al. "Pioglitazone is superior to acarbose in improving glycemic control with type 2 diabetes" American Diabetes Association, Philadelphia 2001: 1 page.
37. Schoonjans K and Auwerx J "Thiazolidinediones: an update" Lancet 2000; 355: 1008- 1010.
38. Food and Drug Administration "Seventy-third meeting of the endocrinologic and metabolic drugs advisory committee" April 22, 1999: 295 pages.
39. King AB "A comparison in a clinical setting of the efficacy and side effects of three thiazolinediones" Diabetes Care 2000; 23 (4): 557.
40. King AB and Armstrong D "Comparison of the glucose and lipid effects of rosiglitazone (ROS) and pioglitazone (PIO) following conversion from troglitazone (TRO) treatment" Diabetes 2001; 50 (Suppl. 2) (abstract 482-P). Website www.diabetes.org consulted on 6 February 2002.
41. Khan AM et al. "A prospective, randomized comparison of the metabolic effects of pioglitazone vs rosiglitazone in patients with type 2 diabetes who where previously treated with troglitazone" Diabetes 2001; 50 (Suppl. 2) (abstract 477-P). Website: www.diabetes.org consulted on 6 February 2002.
42. Davidson PC et al. "Pioglitazone versus rosiglitazone therapy in randomized follow-up in patients previously treated with troglitazone" Diabetes 2001; 50 (Suppl. 2) (abstract 437-P). Website www.diabetes.org consulted on 6 February 2002.
43. Gegick C and Altheimer M "Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice" Endocrine Practice 2001; 7 (3): 162-169 + 2001; 7 (4): 330.
44. Boyle PJ et al. "Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records" Clin Ther 2002; 24 (3): 378-396.
45. "Pioglitazone - Revised labelling: cardiac failure" WHO Pharmaceuticals Newsletter 2000; (4): 7.
46. Belcher G and Matthews DR "Safety and tolerability of pioglitazone" Exp Clin Endocrinol Diabetes 2000; 108 (suppl. 2): 267-273.
47. Forman LM et al. "Hepatic failure in a patient taking rosiglitazone" Ann Intern Med 2000; 132 (2): 118-121.
48. Al-Salman J et al. "Hepatocellular injury in a patient receiving rosiglitazone" Ann Intern Med 2000; 132 (2): 121-124 + Rect. 133 (3): 237.
49. Ravinuthala RS and Nori U "Rosiglitazone toxicity" Ann Intern Med 2000; 133 (8): 658.
50. Hachey DM et al. "Isolated elevation of alkaline phosphatase level associated with rosiglitazone" Ann Intern Med 2000; 133 (9): 752.
51. Gouda HE et al. "Liver failure in a patient treated with long-term rosiglitazone therapy" Am J Med 2001; 111 (7): 584-585.
52. McMorran M and Vu D "Rosiglitazone (Avandia): hepatic, cardiac and hematological reactions" Canadian ADR Newsletter2001; 11 (3): 3-5.
53. Maeda K "Hepatocellular injury in a patient receiving pioglitazone" Ann Intern Med 2001; 135 (4): 306.
54. May LD et al. "Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy" Ann Intern Med 2002; 136 (6): 449-452.
55. Chase MP and Yarze JC "Pioglitazone-associated fulminant hepatic failure" Am J Gastroenterol 2002; 97 (2): 502.
56. Food and Drug Administration "Meeting number 74 of the endocrinologic and metabolic drugs advisory committee" May 19, 2000: 154 pages.
57. Cataldo NA et al. "Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone" Fertil Steril 2001; 76 (5): 1057-1059.
58. Sattar N et al. "Insulin-sensitising agents in polycystic ovary syndrome" Lancet 1998; 351: 305-307.
59. Hanefeld M "Pharmacokinetics and clinical efficacy of pioglitazone" IJCP 2001 (Suppl. 121): 19-25.
60. Prescrire Editorial Staff "NSAIDs: heart failure" Prescr Int 2001; 10 (56): 182-183.
61. Raskin P et al. "Repaglinide/rosiglitazone combination therapy of type 2 diabetes" Diabetes 2001; 50 (suppl. 2): 128 abstract 516-P. Website www.diabetes.org consulted on 6 February 2002.
62. Jovanovic L et al. "Repaglinide/rosiglitazone combination therapy of type 2 diabetes" Diabetes 2001; 50 (suppl. 2): 439 abstract 1830-PO.
63. Gillies PS et Dunn CJ "Pioglitazone" Drugs 2000; 60 (2): 333-343.
64. Banerji M et al. "Rosiglitazone selectively increases subcutaneous but not visceral adipose tissue mass in type 2 diabetes mellitus" Diabetes 2001; 50 (suppl. 2): abstract 356-P. Website www.diabetes.org consulted on 6 February 2002.
65. Miyazaki Y et al. "Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in patients with type 2 diabetes mellitus" Diabetes 2000; 49 (suppl. 1): 299 abstract 1245-P.
66. Rubin CJ et al. "Echocardiographic assessment in patients with type 2 diabetes mellitus treated with pioglitazone" American Diabetes Association, Philadelphia 2001: 1 page.